<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003064</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065734</org_study_id>
    <secondary_id>CPMC-IRB-7866</secondary_id>
    <secondary_id>NCI-G97-1327</secondary_id>
    <nct_id>NCT00003064</nct_id>
    <nct_alias>NCT00034320</nct_alias>
  </id_info>
  <brief_title>Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer</brief_title>
  <official_title>Phase I-II Study of Tandem Cycles of High Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Support in Women With Persistent, Refractory or Recurrent Advanced (Stage III or IV), Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Irving Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy and autologous&#xD;
      peripheral stem cell transplantation in treating patients with recurrent or persistent&#xD;
      epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of topotecan with a fixed dose of etoposide&#xD;
           phosphate as a component of a multicourse high dose chemotherapy regimen supported by&#xD;
           peripheral blood stem cell transplantation in patients with persistent or recurrent&#xD;
           ovarian epithelial, fallopian tube, or primary peritoneal cancer.&#xD;
&#xD;
        -  Evaluate the response, time to progression, disease free survival, and overall survival&#xD;
           in this patient population.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of topotecan.&#xD;
&#xD;
      All patients receive induction therapy consisting of 1 to 2 courses of mobilization therapy.&#xD;
      Subcutaneous filgrastim (G-CSF) is given beginning 24 hours after induction dose. Following&#xD;
      induction therapy, peripheral blood stem cells (PBSC) are harvested. After patients receive&#xD;
      high dose paclitaxel and carboplatin chemotherapy, a portion of the PBSC are reinfused. When&#xD;
      patients recover from the paclitaxel/carboplatin chemotherapy the administration of topotecan&#xD;
      and etoposide phosphate begins. Topotecan is administered, as a 72 hour continuous infusion,&#xD;
      according to a dose escalation schedule with a fixed dose of etoposide phosphate. A second&#xD;
      portion of PBSC are reinfused after topotecan/etoposide phosphate chemotherapy. A course of&#xD;
      thiotepa is given along with the final portion of PBSC after treatment with topotecan and&#xD;
      etoposide phosphate.&#xD;
&#xD;
      Dose escalation of topotecan continues until the maximum tolerated dose (MTD) is determined.&#xD;
      The MTD is defined as the dose preceding that at which 2 or more patients experience dose&#xD;
      limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and every 4 months thereafter to determine&#xD;
      progression free and overall survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 25-30 patients will be accrued for the phase I portion of&#xD;
      this study, and 25 more patients will be accrued for the phase II portion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 1997</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven persistent or recurrent ovarian epithelial, fallopian tube, or&#xD;
             primary peritoneal cancer following at least 3 courses of initial standard platinum&#xD;
             based chemotherapy OR have radiologic evidence of recurrence with a CA125 greater than&#xD;
             100&#xD;
&#xD;
          -  Initial stage IV disease having a complete response following platinum based therapy&#xD;
             allowed&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
          -  Not eligible for other high priority national or institutional study&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1500/mm3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times normal&#xD;
&#xD;
          -  SGOT or SGPT less than 1.5 times normal&#xD;
&#xD;
          -  PT/PTT within normal limits&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN less than 1.5 times normal&#xD;
&#xD;
          -  Creatinine less than 1.5 times normal&#xD;
&#xD;
          -  Creatinine clearance greater than 55 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 45%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No prior malignancy other than curatively treated carcinoma in situ of the cervix,&#xD;
             nonmelanoma skin cancer, or breast cancer if the risk of recurrence is sufficiently&#xD;
             low&#xD;
&#xD;
          -  No serious illness that would prevent treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent acetaminophen&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy D. Tiersten, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2003</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

